ADAG — Adagene Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1818838 ·
Last close
$3.20
Market Cap
$214.86M
52W High
$4.85
52W Low
$1.30
ADV30
247,012
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 133,575,568 | 127,909,840 | 44,122,150 |
| Dec 2025 | — | — | — | — | 78,263,297 | 74,523,782 | 42,913,750 |
| Jun 2025 | — | — | — | — | 66,516,743 | 62,828,156 | 28,604,954 |
| Dec 2024 | — | — | — | — | 89,268,425 | 85,194,502 | 38,744,581 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-328,785,000
Inventory
—
Receivables
$17,349
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$9,290,815
EBITDA
$-21,952,354
Free Cash Flow
$-12,158,853
Enterprise Value
$123,018,568
Total Cash
$127,909,840
Total Debt
$6,091,037
Shares Out
67,143,344
Trailing EPS
$-0.38
Book Value
$1.33
ROE
-28.5%
ROA
-14.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,670,902 | -21,438,295 | -17,609,413 | 78,263,297 | 42,913,750 | 35,349,547 | -15,657,450 |
| Dec 2024 | 103,204 | -35,951,543 | -33,424,111 | 89,268,425 | 38,744,581 | 50,523,844 | -29,700,985 |
| Dec 2023 | 18,111,491 | -23,719,866 | -18,946,370 | 115,728,838 | 45,169,341 | 70,559,497 | -28,454,839 |
| Dec 2022 | 9,292,724 | -83,920,683 | -79,971,847 | 152,399,845 | 69,309,495 | 83,090,350 | -48,611,687 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.56
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ELDN | Eledon Pharmaceuticals, Inc. | $214.53M | $2.64 | — |
| WHWK | Whitehawk Therapeutics, Inc. | $214.35M | $3.76 | — |
| RNAC | Cartesian Therapeutics, Inc. | $218.14M | $7.21 | — |
| FHTX | Foghorn Therapeutics Inc. | $209.04M | $3.52 | — |
| KROS | Keros Therapeutics, Inc. | $223.65M | $11.28 | — |
News headlines (Yahoo Finance, 1h cache)
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
2026-09-22 12:00 · Yahoo
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
2026-09-10 12:00 · Yahoo
Adagene to Participate in Three Upcoming Investor Conferences
2026-08-20 12:00 · Yahoo
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know
2026-06-05 16:00 · Yahoo
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
2026-05-19 21:07 · Yahoo
Adagene to Participate in Two Upcoming Investor Conferences
2026-05-12 12:30 · Yahoo
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Col
2026-04-02 11:01 · Yahoo
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
2026-04-17 20:01 · Yahoo
Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer
2026-04-20 14:15 · Yahoo
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
2026-04-14 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.